8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
May 6, 2026·SEC
Material company update
Apr 21, 2026·SEC
Milestone Scientific Inc.(MLSS)Earnings, Financials & Key Ratios
MLSS•AMEX
$0.32
Price updated Jun 27, 2026
AboutMilestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.Show more
- Revenue$9M+4.0%
- EBITDA-$6M+18.0%
- Net Income-$6M-21.4%
- EPS (Diluted)-0.07-18.4%
- Gross Margin70.53%-5.4%
- EBITDA Margin-61.41%+21.1%
- Operating Margin-63.48%+18.9%
- Net Margin-63.76%-16.7%
- ROE-132.38%-94.4%
MLSS Price & Volume
Milestone Scientific Inc. (MLSS) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Threaten Capital Runway Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and capital exhaustion
"Milestone Scientific faces significant structural challenges as it struggles to scale its proprietary dental technology, evidenced by a consistent inability to convert high gross margins into positive operating income. The company's reliance on substantial SG&A spending, which frequently exceeds $2.5 million per quarter, continues to erode shareholder equity and deplete cash reserves. Investors should remain cautious as the narrowing liquidity buffer and history of $134.6 million in accumulated losses suggest a high probability of future dilutive financing events."
Verdict Logic
the company's inability to achieve operating leverage, combined with a rapidly depleting cash balance of $1.2 million against quarterly operating losses, presents an unsustainable risk profile for long-term investors.
MLSS Growth Metrics
Milestone Scientific Inc. (MLSS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-0.56%
5 Years10.54%
3 Years0.63%
TTM3.37%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM13.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.68%
Return on Capital
10 Years-101.84%
5 Years-79.32%
3 Years-95.77%
Last Year-117.12%
MLSS Recent Earnings
Milestone Scientific Inc. (MLSS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.01+33.3%
$0.01
Rev
$2M-4.0%
$2M
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.02-33.3%
$0.01
Rev
$2M-10.6%
$2M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.01+33.3%
$0.01
Rev
$2M+2.2%
$2M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.02-100.0%
$0.01
Rev
$2M+1.0%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.01vs $0.01+33.3% | $2Mvs $2M-4.0% |
| Q2 2026 | Mar 31, 2026 | $0.02vs $0.01-33.3% | $2Mvs $2M-10.6% |
| Q4 2025 | Nov 13, 2025 | $0.01vs $0.01+33.3% | $2Mvs $2M+2.2% |
| Q3 2025 | Aug 14, 2025 | $0.02vs $0.01-100.0% | $2Mvs $2M+1.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Milestone Scientific Inc. (MLSS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.32 | $28.16M | -4.57 | 3.99% | -63.76% | -132.38% | — | |
| $11.01 | $2.21B | -3.67 | -2.98% | -17.06% | -41.19% | — | |
| $84.95 | $9.68B | 25.98 | 4.03% | 2.95% | 8.14% | — | |
| $26.96 | $4.39B | 96.29 | 8.32% | 2.41% | 2.18% | — | |
| $178.43 | $12.78B | 31.58 | 0.9% | 10.5% | 10.7% | — | |
| $42.98 | $614.51M | -52.41 | -4.91% | -14.59% | -15.59% | — |
Compare MLSS vs Peers
Milestone Scientific Inc. (MLSS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MLSS SEC Filings & Documents
Milestone Scientific Inc. (MLSS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when MLSS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MLSS Frequently Asked Questions
Milestone Scientific Inc. (MLSS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Milestone Scientific Inc.'s revenue?
Milestone Scientific Inc. (MLSS) reported $8.9M in revenue for fiscal year 2025. This represents a 2868% increase from $0.3M in 1996.
How fast is Milestone Scientific Inc. growing?
Milestone Scientific Inc. (MLSS) grew revenue by 4.0% over the past year. Growth has been modest.
Is MLSS profitable?
Milestone Scientific Inc. (MLSS) reported a net loss of $4.6M for fiscal year 2025.
Dividend & Returns
What is MLSS's return on equity?
Milestone Scientific Inc. (MLSS) has a return on equity (ROE) of -132.4%. Negative ROE indicates the company is unprofitable.
What is Milestone Scientific Inc.'s free cash flow?
Milestone Scientific Inc. (MLSS) had negative free cash flow of $1.8M in fiscal year 2025, likely due to heavy capital investments.